Active, not recruiting • Phase I, II • Stage III, IV • Post-Menopausal • Interventional
The following is imported from ClinicalTrials.gov:
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
Breast Cancer
Study Design
Study type:
Interventional
Estimated enrollment:
170 participant
Actual study start date:
October 9, 2019
Eligibility Criteria
Ages eligible for study:
18 - 999
Sexes eligible for study:
both
Arms and Intervention
CYT-0851
CYT-0851 in combination with gemcitabine
CYT-0851 in combination with capecitabine
CYT-0851 in combination with rituximab and bendamustine